U.S. Beverage Stock News

NYSE:VEEV
NYSE:VEEVHealthcare Services

Veeva (VEEV) Stock May Be 30% Undervalued As Cash Flows Hold Up

Veeva Systems stock has had a difficult longer term run, with the share price down about 39% over the past 5 years, while the current valuation signals send mixed messages. The intrinsic value estimate based on a Discounted Cash Flow (DCF) model points to meaningful upside compared with the current price, while market multiples suggest the stock screens as expensive. Over 5 years the share price has declined about 39%, which means recent investors are still carrying material capital losses...
NasdaqGS:SEDG
NasdaqGS:SEDGSemiconductor

Texas Instruments Stock Leads 3 Dollar Beneficiaries Built For Higher Yields

US dollar beneficiaries are back in focus as investors weigh stubborn inflation signals, a 5.23% US 30-year Treasury yield, and higher oil prices linked to conflict in Iran and shipping risks in the Strait of Hormuz. When borrowing costs jump and policy signals feel uncertain, exporters and multinationals with meaningful foreign earnings can behave very differently from purely domestic stocks. This article walks through 3 stocks from a US Dollar Beneficiaries screener that appear positively...
NYSE:DT
NYSE:DTSoftware

Dynatrace (DT) Following Its AI Platform Expansion And Gremlin Tie Up Looks Undervalued

Dynatrace (DT) has drawn fresh attention after rolling out new Dynatrace Intelligence capabilities and a deeper Gremlin integration that bring autonomous incident response and built in reliability testing into its AI powered observability platform. See our latest analysis for Dynatrace. Recent product news and the appointment of AI focused executive Chandu Thota have arrived as the Dynatrace share price sits at US$43.88, with a 90 day share price return of 21.18% but a 1 year total...
NasdaqGS:AGNC
NasdaqGS:AGNCMortgage REITs

AGNC Investment (AGNC) Looks Cheap As Strong Q2 Earnings Put Valuation Back In Focus

AGNC Investment (AGNC) reported second quarter 2026 earnings on July 20, with net income of US$654 million compared with a net loss of US$140 million a year earlier. Basic earnings per share were US$0.53. See our latest analysis for AGNC Investment. At a recent share price of US$10.90, AGNC Investment has seen short term share price returns move slightly in both directions. However, the 1 year total shareholder return of 30.37% and 3 year total shareholder return of 66.91% point to stronger...
NasdaqGS:AMZN
NasdaqGS:AMZNMultiline Retail

E-Commerce Update - Retail Evolution Insights From 2027 Market Research Report

The recently released "Retail & E-Commerce Market Research 2027" report provides a comprehensive evaluation of the retail and e-commerce landscape, combining extensive market data and trend analysis. This research offers insights into consumer spending, industry trends, and competitive dynamics, aiding strategic decision-making for businesses in both digital and physical retail spaces. The report features historical and year-end data across various sectors, financial performance reviews of...
NYSE:B
NYSE:BMetals and Mining

Barrick Mining (B) Stock Looks Stretched As Its 135% 3 Year Run Continues

Barrick Mining has delivered a strong 135.5% return over the past 3 years, yet today's valuation picture is mixed, with the Discounted Cash Flow (DCF) intrinsic value pointing to a premium to the current share price while market multiples suggest the stock may still be inexpensive. For investors, that split between models raises questions about how much of Barrick Mining's recent share price strength is already reflected in the fundamentals. The 135.5% gain over 3 years highlights how...
NasdaqGM:APPN
NasdaqGM:APPNSoftware

Appian (APPN) Stock Could Be A Bargain On Cash Flow Despite Weak Returns

Appian stock has rebounded in the short term, yet both the Discounted Cash Flow (DCF) intrinsic value estimate and the broader valuation checks still point to shares trading below what the underlying cash flows suggest. Appian shareholders have seen the stock fall 73.8% over the past 5 years, which puts recent gains into the context of a long period of weak returns. The investment case may hinge on whether Appian can convert its software platform into stronger, more predictable cash flows,...
NasdaqGS:ROP
NasdaqGS:ROPSoftware

Why Roper Technologies (ROP) Is Up 14.9% After Q2 EPS Surge And Completed Buyback Program

Roper Technologies recently reported past second-quarter 2026 results showing sales of US$2,108.9 million and net income of US$1.17 billion, alongside a completed buyback of 8,995,000 shares for US$3.20 billion under its October 2025 authorization. The sharp uplift in quarterly earnings per share from continuing operations, combined with sizeable share repurchases, highlights how operational performance and capital allocation are working together to reshape Roper’s financial profile. We’ll...
NasdaqGS:QCOM
NasdaqGS:QCOMSemiconductor

Qualcomm (QCOM) Buys Modular And Lands BMW Deal For AI Vehicles

Qualcomm (NasdaqGS:QCOM) has completed its acquisition of Modular Inc, an AI native software infrastructure company. The company has also entered a long term semiconductor supply agreement with BMW Group for next generation AI powered vehicle platforms. Both developments expand Qualcomm's role in AI centric computing and automotive technology beyond its core mobile business. These moves place Qualcomm more firmly at the center of two large themes investors are watching closely: AI compute...
NasdaqGS:ONC
NasdaqGS:ONCBiotechs

Is BeOne Medicines (ONC) Stock Priced For Perfection On Earnings?

BeOne Medicines stock has delivered a 59.0% return over the past three years, yet the current checks flag it as screening on the expensive side rather than as an obvious bargain. BeOne Medicines has returned 59.0% over three years, which puts extra focus on whether the current share price still leaves enough value support for new investors. Future revenue and cash flow expectations can support the current valuation, while any setback in execution or higher funding needs could quickly reduce...
NasdaqGM:FRPT
NasdaqGM:FRPTFood

Freshpet (FRPT) Stock May Be 36% Below Fair Value As Cash Flow Hope Builds

Freshpet stock sits at an interesting crossroad today. The Discounted Cash Flow (DCF) intrinsic value estimate points to a sizeable gap to the upside, while market based valuation multiples lean the other way and suggest the shares are on the expensive side. Over the past 5 years, Freshpet shares have declined 55.5%, which places the current valuation debate against a backdrop of weak long term returns. For a company like Freshpet, expectations for sustained revenue growth and progress...
NasdaqGS:AMSC
NasdaqGS:AMSCElectrical

American Superconductor (AMSC) Stock Could Be 31% Undervalued Following A $25 Million Contract

American Superconductor stock has pulled back sharply in the short term, yet the intrinsic value estimate using a Discounted Cash Flow (DCF) approach points to a sizeable gap between the recent share price and what the cash flows suggest the business could be worth. With market multiples also screening the stock as undervalued, investors are weighing whether recent weakness or the valuation signals deserve more attention. American Superconductor has returned 132.5% over the past 3 years,...
NasdaqGS:USLM
NasdaqGS:USLMBasic Materials

United States Lime & Minerals (USLM) Stock Looks Fairly Valued On Cash Flow Yet Rich On Earnings

United States Lime & Minerals has delivered very strong long term share price gains over the past 5 years, yet its low value score and mixed valuation signals suggest the stock may no longer be an obvious bargain at around US$113 per share. The stock has returned about 298% over 5 years, which puts extra focus on whether that past performance is already priced into today’s valuation. Rising demand from construction and steel customers and the planned ramp up of a new kiln may support future...
NasdaqGS:INCY
NasdaqGS:INCYBiotechs

Incyte (INCY) Wins European Approval For Opzelura In Adult Atopic Dermatitis

Incyte received European Commission approval for Opzelura (ruxolitinib) cream to treat moderate atopic dermatitis in adults. This is Opzelura's second indication in Europe following its earlier approval for non segmental vitiligo. The decision expands Incyte's dermatology footprint in Europe and adds a new potential use case for Opzelura. For investors tracking Incyte, ticker NasdaqGS:INCY, the European approval for Opzelura comes as the stock trades at $127.1. The company has posted...
NasdaqGM:EYPT
NasdaqGM:EYPTPharmaceuticals

EyePoint (EYPT) Settles DOJ Claims, Is The 71% Undervaluation Case Convincing?

EyePoint (EYPT) has entered a settlement with the U.S. Department of Justice and related agencies over past DEXYCU commercialization practices, agreeing to specified payments and a five year Corporate Integrity Agreement, without admitting liability. See our latest analysis for EyePoint. Set against this legal resolution, EyePoint's recent share price return has softened, with the stock down 15.52% over 30 days and 31.81% year to date. However, the 1 year total shareholder return is 21.14%,...
NasdaqGM:QCRH
NasdaqGM:QCRHBanks

Undervalued Small Caps With Insider Action To Watch In July 2026

Over the last 7 days, the United States market has experienced a 2.6% decline, yet it remains up by 14% over the past year, with earnings anticipated to grow by 17% annually in the coming years. In this dynamic environment, identifying small-cap stocks with insider activity can provide valuable insights into potential opportunities for investors seeking to navigate these market conditions effectively.